Yahoo Finance

Overview: Neurones S.A. is an IT services company offering infrastructure, application, and consulting services both in France and internationally, with a market cap of €1.03 billion.

Operations: Neurones S.A. generates revenue primarily from Infrastructure Services (€468.49 million), Application Services (€219.47 million), and Council services (€53.21 million).

Neurones, an IT services firm, has demonstrated robust financial health with earnings growth of 11.7% over the past year and high-quality earnings. The company’s debt to equity ratio increased from 0.1% to 1.8% in five years, yet it holds more cash than its total debt. Trading at 16.6% below estimated fair value and forecasting close to €800 million in revenues for 2024 with a net profit margin around 9.5%, Neurones appears well-positioned for sustained performance within its industry context where it outpaced average sector growth by a significant margin last year.

• Unlock comprehensive insights into our analysis of Neurones stock in this health report.

• Explore historical data to track Neurones' performance over time in our Past section.

Roche Bobois

Simply Wall St Value Rating: ★★★★★☆

Overview: Roche Bobois S.A. engages in the furniture design and distribution business worldwide with a market cap of €484.02 million.

Operations: Roche Bobois generates revenue primarily from its Roche Bobois USA/Canada (€150.21 million), Roche Bobois France (€118.72 million), and Roche Bobois Europe excluding France (€105.94 million) segments, with additional contributions from Cuir Center (€43.39 million) and corporate activities (€4.14 million).

Roche Bobois, a notable player in the luxury furniture market, has demonstrated robust financial health. Over the past five years, its debt to equity ratio improved from 39.5% to 33.4%, and it currently holds more cash than total debt. Trading at 51% below our fair value estimate, RBO's high-quality earnings have grown an impressive 34.9% annually over this period. Despite a modest earnings growth of 0.2% last year, profits are forecasted to increase by 11% yearly moving forward.

• Get an in-depth perspective on Roche Bobois' performance by reading our health report here.

• Understand Roche Bobois' track record by examining our Past report.

Where To Now?

• Get an in-depth perspective on all 34 Euronext Paris Undiscovered Gems With Strong Fundamentals by using our screener here.

• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.

• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ENXTPA:ES ENXTPA:NRO and ENXTPA:RBO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com